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Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and
sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has
defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse
transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside GD2 and tyrosine hydroxylase mRNA respectively. The
INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral
blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before
and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of
harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results
and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual
disease in heterogeneous patient groups.
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The clinical course of neuroblastoma (NB) varies greatly in
individual children depending on age, stage, histology and a
number of genetic features (Brodeur, 2003; Maris et al, 2007). It is
anticipated that the prognostic and predictive significance of such
features will allow the identification of those children at greatest
risk of relapse and poor outcome, leading to improved stratifica-
tion for treatment and increased survival. The clinical significance
of different prognostic factors is best assessed in large, coopera-
tive, quality-controlled multi-centre prospective clinical trials.
However before inclusion into such studies, children must be
staged according to consensus risk criteria. One of the most
important hallmarks of aggressive high-risk disease in children
with NB is the dissemination of disease to the bone marrow (BM).
The accurate detection of this disease is fundamental to the staging
of children at diagnosis, this staging defining the initial treatment
course. To guarantee consistency in the results collected in
different laboratories, prognostic factors and metastatic disease
should be evaluated by applying consensus standard operating
procedures (SOPs) in all participating institutions.
The goal of the International Neuroblastoma Risk Group (INRG)
Task Force is to achieve an international consensus on SOPs to
improve and standardise management of children with NB.
Established in 2004, the INRG Task Force constitutes experts
across the different disciplines recruited from the major coopera-
tive groups in America, Europe and Japan, as well as investigators
from Australia and China. Four committees have been convened.
The statistical, surgical and biological committees developed the
INRG Risk Classification based on the statistical analysis of
relevant clinical, histological and genetic factors (Cohn et al, 2009)
and the INRG Staging System (INRGSS) based on clinical criteria
and image defined risk factors (Monclair et al, 2009). Consistent
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swith the International Neuroblastoma Staging System (INSS) and
the International Neuroblastoma Response Criteria (Brodeur et al,
1988, 1993), the INRGSS (Monclair et al, 2009) proposes to
evaluate BM for metastatic disease at diagnosis and following
treatment.
For the purpose of initial staging at diagnosis, morphological
investigations by cytological screening of bilateral BM aspirates
and histological assessment of bilateral core biopsies are
recommended. The INRGSS defines a BM infiltration of 10%
tumour cells as the critical level to distinguish between those
patients with stage M and MS metastatic disease, which can be
achieved using conventional cytology. However, cytological and
histological techniques have limited sensitivity and are unable to
reliably detect minimal disease (MD) (Cheung et al, 1997).
Furthermore, conventional cytomorphology and histology do not
give an exact quantification of infiltrating tumour cell number.
Therefore, for most children during or after completion of therapy,
more sensitive methods for the detection of minimal residual
disease (MRD) are needed. One of the most important tasks for the
fourth committee, the Metastatic Disease Committee, has been to
define common methodologies for the sensitive and accurate
detection of MD and MRD in BM aspirates, peripheral blood (PB)
and peripheral blood stem cell (PBSC) harvest. The two methods
that have been systematically standardised are immunocytology
(IC) targeting single tumour cells and ribonucleic acid (RNA)-
based reverse transcriptase-polymerase chain reaction (RT–PCR).
Single-cell-based methods for detection of MD
Increased sensitivity and accurate quantification of the number of
infiltrating tumour cells may be achieved by single-cell-based
analytical methods, for example IC and flow cytometry (FC). Both
these methods are dependant on the availability of antibodies to
tumour-associated cell-surface and intracellular antigens that
ideally should be expressed on all target NB cells.
Antigens
A variety of neuroectodermal antigens have been applied for
immunocytological and flow cytometric detection of NB cells
(reviewed in Beiske et al, 2005). Many NB-associated antigens are
inappropriate for detection of MD and MRD because of their
heterogeneous expression in individual tumours or co-expression
by normal cells (Sugimoto et al, 1988). In contrast, disialoganglio-
side GD2 is reported to be homogeneously and strongly expressed
on neuroblastic tumours (Schulz et al, 1984; Cheung et al, 1985;
Shochat et al, 1988), but not on normal haematopoietic cells
(Cheung et al, 1986) and is therefore regarded as ideal for specific
and sensitive detection of MD and MRD by IC and FC (Warzynski
et al, 2002, Swerts et al, 2004).
Immunocytology
The specific binding of antibodies to NB cells on cytospins or
smears has been visualised by either cytochemical (Beck et al,
1988) or fluorescent (Favrot et al, 1986) detection method.
For immunocytochemical detection, alkaline-phosphatase-based
techniques are preferred to those using horseradish peroxidase to
avoid false-positive rates due to the abundant expression of the
latter enzyme in normal BM cells. The light microscopic evaluation
of immunocytochemical results allows a detailed cytomorphologi-
cal study of immunopositive and -negative cells. This is important
to distinguish between NB cells and haematopoietic cells that may
have taken up the antigen, for example macrophages. Moreover,
the chromogenic label of positive cells is stable over time,
facilitating sample review in cooperative groups of experts with
the goal of defining standard criteria for evaluation (Swerts et al,
2005), quality control and training of less experienced colleagues.
Establishing immunocytochemistry is relatively inexpensive
because it does not require any specific equipment beyond a
conventional light microscope. Disadvantages of immunocyto-
chemistry include restrictions regarding multi-parameter analyses.
Owing to the chemical nature and size of chromogens, only two
separate markers, preferably located in different cellular compart-
ments, may be detected at the same time. Subsequent analysis with
fluorescent markers is not possible when alkaline phosphate-
driven substrate reactions have been used because the most
commonly involved chromogens display strong autofluorescence.
Fluorescence-based IC offers advantages and disadvantages
differing from those listed above. Fluorochromes are small,
chemically inert molecules representing superior markers
for multi-parameter analyses. Thus, two or more differentially
labelled antibodies, for example directed against neuroblasts and
haematopoietic cells, can be applied simultaneously to increase the
specificity of the immunocytological assay (Combaret et al, 1989).
However, cytomorphological details are difficult to recognise using
a fluorescent microscope. In contrast to the standardisation that
has been achieved with immunocytochemistry (Swerts et al, 2005),
cytomorphological criteria for distinguishing immunofluores-
cence-labelled neuroblasts from falsely positive haematopoietic
cells have never been defined and standardised. Moreover,
fluorescent signals are too weak to be reviewed in a multi-headed
microscope. This implies that the decision on whether neuroblasts
are present in a given sample will be made by only one observer,
thereby increasing the risk from subjective bias. Owing to fading,
fluorescent signals need to be documented by images that do not
always offer the comprehensive information with respect to label
distribution and intensity. These features hamper the quality
control of fluorescence-labelled samples. Fluorescence-based im-
munocytological detection methods are therefore not considered
to be an appropriate tool for sample review, standardisation of
evaluation criteria and training of observers.
Fluorescence-based IC and fluorescence in situ
hybridisation (FISH)
Similar to the simultaneous application of two or more antibodies,
the specificity of immunocytological assays can be enhanced by
subsequent performance of inter-phase cytogenetic investigations
(eg FISH) targeting tumour-specific aberrations in infiltrating NB
cells. In cooperation with an IT company, a European laboratory
working on MD in NB developed a specific software facilitating the
automated screening, imaging and counting of fluorescence-
positive events in a cytological sample after staining with a
fluorochrome-labelled NB-specific antibody (Me ´hes et al, 2000).
The images need to be assessed by an observer who decides
whether a fluorescent cell represents a neuroblast. In addition, the
software records the positions of fluorochrome-positive cells on
the slide and can move the microscope stage to re-localise positive
cells for direct assessment in the microscope. Moreover, doubtful
cells may be targeted by FISH, re-localised and recorded by the
software, and evaluated by the observer either on images or in the
microscope (Me ´hes et al, 2001). Though representing an attractive
tool for validation of immunocytological results, the system is
rarely available among laboratories analysing samples from
children with NB for MD. This most likely reflects the acquisition
costs that are rather high, in part reflecting the limited access to
software that is only available together with a fluorescence
microscope through a single company. The analysis is at least
initially more labour intensive than manual evaluation of samples
by IC because the observer must build a classifier comprising
detailed criteria for automated picking and imaging fluorescent
events. Although sample evaluation is eased by automated
counting, recording and re-localisation of fluorescent cells, the
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sdecision on whether an individual cell is a tumour cell still depends
on the skills of the individual observer. This is likely to be most
critical in suboptimal preserved clinical samples. Moreover, it is
not always possible to unequivocally document antigen expression
and low-copy genetic gains and losses on two-dimensional images.
These restrictions impede the review and quality control of
fluorescent data in a cooperative task group as pointed out
previously.
Flow cytometry
Flow cytometry has been successfully applied by several groups as
a tool for MD analysis in NB patients (reviewed in Beiske et al,
2005). In contrast to IC, the analysis is performed on suspended
cells, which in addition to the expression of specific antigens are
analysed for size and granularity. No other cytomorphological
features can be recorded. All the advantages described for
fluorescence-based IC also apply to FC. The simultaneous
application of differently labelled antibodies against tumour cells
and normal cells secures a high specificity of the analysis. Other
advantages include a fast sample throughput, results being
provided within a few hours. A positive result is defined as a
cluster of at least 10–20 flow cytometric events in a dot plot
(Campana and Coustan-Smith, 2002) and it does not depend on
the cytomorphological, immunological or cytogenetic skills of the
observer. However, FC cannot be regarded as a completely
objective technique because the correct distinction between a few
positive events and a high background depends on the observer’s
personal experience with the instrument and the applied
antibodies.
Sensitivity of single-cell-based assays
The requirement for at least 10–20 events to call a sample positive
clearly limits the sensitivity of flow cytometric analyses because it
means that the sensitivity can not exceed 1 in 10
4 cells if only
2 10
5 cells are available for investigation. Likewise, to reach a
sensitivity of 1 in 10
5 cells, 1 to 2 10
6 cells are required for
analysis. This is not always feasible especially when examining
post-chemotherapy samples. Thus, the sensitivity of flow cyto-
metric analyses depends both on the number of investigated cells
and the presence of at least 10–20 cells expressing the correct
immunophenotype. In most clinical settings this will reach 1 in 10
4
to 10
5 cells.
In contrast, the sensitivity of immunocytological investigations
solely depends on the number of investigated cells because
clustering of positive cells is not required. Several reports have
demonstrated the high sensitivity (1 tumour cell in 10
4 to 10
6
normal cells) of immunocytological assays in BM (Cheung et al,
1986; Favrot et al, 1986; Gussetis et al, 1989), BM autograft
(Combaret et al, 1989) and PB samples (Faulkner et al, 1998).
Swerts et al (2004) compared IC applying only one anti-GD2
antibody to FC involving five differently labelled antibodies against
GD2, CD9, CD81 and CD56 on tumour cells and against CD45 on
haematopoietic cells and concluded that the sensitivity of the flow
cytometric assay was about 10 times lower if equal amounts of cells
were analysed.
Although some immunocytological studies indicate that the level
of BM infiltration is associated with outcome in children with stage
3 and 4 NB (Moss et al, 1991; Seeger et al, 2000), thus far it is not
known what level of MD is clinically relevant. Therefore which
methodology will be most suitable for the detection of this disease
is not clear. However, it is crucial to be aware of the differential
sensitivity of methods when low numbers of tumour cells are
expected in a clinical sample. Information about sensitivity is also
crucial when studies are designed to identify MD levels of clinical
relevance because only MD results collected at similar levels of
sensitivity are comparable to each other. Therefore, the number of
cells examined must be included in each report.
Nucleic-acid-based detection of MD
The amplification of tumour-specific or tumour-associated mRNA
by RT–PCR has made an enormous impact on the sensitivity and
specificity of tumour cell detection, allowing the accurate, objective
detection of a single tumour cell in up to 1 10
6 normal cells. This
technique has been used to detect MD and MRD in a number of
different cancers where target mRNAs expressed in tumour cells
but not in the cells of the compartment to be studied (eg BM, PB,
PBSC) have been identified. Importantly like cell-based methods,
the presence of tumour-specific or tumour-associated mRNA is
thought to reflect the presence of the disseminating tumour cell or
cells that may have the capacity to metastasise, and consequently
may more closely reflect active disease status. This is in contrast to
the detection of circulating free nucleic acid in plasma, serum or
urine that may be useful in cancer detection, prognostication and
monitoring (Taback and Hoon, 2004; Zeerleder, 2006; O’Driscoll,
2007) but reflects tumour turnover and mass.
Optimal target selection for detection of MD by RT–PCR
Polymerase chain reaction-based amplification of tumour-specific
abnormalities to detect MD has been most powerful in haemato-
logical malignancies where consistent, well-characterised translo-
cations have been described. These studies have resulted in the
introduction of new interventions to target this disease with the
expectation of improved patient outcome (Faderl et al, 1999;
Foroni et al, 1999; Hochhaus et al, 2000; Roman et al, 2000;
Campana et al, 2001). Amplification of known tumour-specific
gene rearrangements has also provided a powerful tool to detect
potential significant MD in solid cancers including those of the
Ewing’s sarcoma family of tumours (de Alava et al, 1998; Zoubek
et al, 1998; Schleiermacher et al, 2003; Avigad et al, 2004), alveolar
rhabdomyosarcoma (Thomson et al, 1999; Athale et al, 2001;
Gallego et al, 2006) and desmoplastic small round cell tumours
(Athale et al, 2001).
Unfortunately for most solid tumours, tumour-specific gene
abnormalities that can be exploited to detect MD have not been
identified. In these cases amplification of tumour-associated wild-
type mRNA by RT–PCR has been used (Burchill and Selby, 1999,
2000). Optimal detection of MD or MRD using RT–PCR for
wild-type mRNAs requires the identification of a target mRNA
that is expressed in the target tumour cells but not in normal
haematopoietic cells or cells within the compartment to be
studied. Ideally a target for the detection of MD by RT–PCR will
not only be cell specific, it will also have a long half-life and
expression will be unaffected by chemotherapeutics, allowing an
assessment of MRD throughout treatment and the disease course.
A tissue-specific wild-type mRNA should also be encoded by a
gene with introns so that primers for amplification by PCR can be
designed across exon–exon junctions, to selectively amplify cDNA
generated from mRNA and limit any false positives generated from
amplification of contaminating genomic DNA. The identification
of suitable target mRNAs is one of the primary challenges
for successful application of RT–PCR to detect MD in most
solid cancers.
Target selection in NB
The application of RT–PCR to detect MD in children with NB has
been studied by several groups, and a number of different target
mRNAs have been explored. Because catecholamines are produced
by NB, the mRNA for the first enzyme in the catecholamine
synthesis pathway tyrosine hydroxylase (TH) was used in initial
proof-of-principle experiments. Using TH as a target detection of 1
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sNB cell in 10
6 normal cells is frequently reported. Although other
targets for the detection of NB cells by RT–PCR have been
described, TH mRNA is currently the single most widely evaluated
target (Burchill et al, 1994; Miyajima et al, 1995; Gilbert et al, 1997;
Cheung and Cheung, 2001; Tchirkov et al, 2003; Ito et al, 2004;
Ootsuka et al, 2008; Tra ¨ger et al, 2008). Clinically significant
disease has been detected in PB (Burchill et al, 1995, 2001a; Kuroda
et al, 1997; Shono et al, 2000; Cheung et al, 2004) and BM
(Miyajima et al, 1996; Kuroda et al, 1997; Shono et al, 2000;
Fukuda et al, 2001; Horibe et al, 2001) samples from children with
NB at diagnosis, on therapy, during follow-up and at relapse by
RT–PCR for TH. Furthermore, this technique has been used to
detect NB cells in PBSC from children with high-risk disease
(Miyajima et al, 1996; Burchill et al, 2001b; Corrias et al, 2006).
The success of TH as a target is in part attributed to the stability of
the mRNA in haemopoietic compartments and its ubiquitous
expression in NB cells; even those rare NB cells that do not secrete
catecholamines express TH mRNA. Furthermore, most studies
suggest that TH mRNA is absent or rarely expressed in normal PB
or BM (Burchill et al, 1995; Cheung and Cheung, 2001; Tra ¨ger et al,
2008; Viprey et al, 2008). Despite this literature the clinical utility
of RT–PCR for TH mRNA remains unclear, reflecting the small
number of patients studied, absence of quality control across
studies, lack of uniform methodology for sample collection,
processing and inconsistency in reporting (Riley et al, 2003).
Therefore the clinical utility of RT–PCR for TH mRNA is currently
being evaluated in a large prospective clinical trial (HR-NBL1/
ESIOP; www.siopen-r-net.org), according to quality-controlled
SOPs (Viprey et al, 2007).
Quantitative (Q)RT-PCR
The development of quantitative reverse transcriptase-polymerase
chain reaction (QRT-PCR) has increased the scope and potential
for MD monitoring by RT–PCR, providing assays with a wider
linear dynamic range, superior sensitivity and objective inter-
pretation of results. These properties are enhanced by good intra-
and inter-assay reproducibility, and the generation of a permanent
quantitative record of the data that can be reviewed independently.
Additional attractions include high-throughput capacity, speed
and elimination of lengthy post-PCR handling steps, reducing the
risk of potential carryover contamination.
A further obvious advantage of QRT-PCR over more traditional
qualitative RT–PCR is that it allows a precise quantification of a
single or multiple mRNA(s) in clinical samples. This is not
necessarily a direct measure of absolute cell number because the
level of a target mRNA per cell may vary, however it does allow an
objective accurate measure of tumour content within and across
clinical samples. This is particularly important for defining the
clinically relevant level of MD and MRD at diagnosis and during
disease course respectively. For accurate reporting the selection of
an optimal reference mRNA against which the test mRNA(s) can be
normalised is essential (Beillard et al, 2003; Viprey et al,2 0 0 7 ) .b-2
microglobulin (b2M) is frequently selected as the standard house-
keeping gene to report expression of MD in BM, PB and/or PBSC as
it is stably expressed in normal haematopoietic cells (Livak and
Schmittgen, 2001; Beillard et al, 2003). Some investigators use
target-specific calibrators that allow the accurate quantitation of
transcript number within a sample (Trager et al, 2003), although
this must be reported relative to transcript number
of a housekeeping gene to control for inter-assay variability
(especially when different machines and/or thresholds are used).
The ability to quantify the level of specific mRNAs also facilitates the
development of assays with increased specificity of tumour cell
detection where an ideal target has not been identified, overcoming
tumour heterogeneity and low-level expression of some target
mRNAs in cells of the normal compartments (Cheung and Cheung,
2001; Swerts et al,2 0 0 6 ;C h e u n get al,2 0 0 7 ;M e d i cet al, 2007; Viprey
et al, 2008). Where it has not been possible to identify specific wild-
type targets for detection of disease, this can be particularly
powerful based on the ability to experimentally define a cut-off to
distinguish between clinically significant levels of tumour cell
mRNA and levels in normal cells (Gunn et al, 1996; Swerts et al,
2006; Cheung et al,2 0 0 7 ) .
CONSENSUS METHODS
Although IC and RT–PCR appear to be ideal tools for monitor-
ing MD and MRD with a sensitivity of 1 tumour cell in 10
5 to 10
7
normal cells, their integration into the management of children
with NB has been slow. This reflects uncertainty about clinical
utility, which in part is a consequence of the small number of
children studied but also inconsistency of methods and reporting
making it difficult to compare results from different centres and
countries. After in-depth discussions of the advantages and
disadvantages of the available methods reviewed above, the
members of the Metastatic Disease Committee agreed on
consensus criteria for the collection and processing of haemato-
poietic samples and for the detection of rare NB cells in BM, PB
and PBSC by IC using GD2 and by QRT-PCR for TH mRNA. The
recommendations are reported here and include guidelines for the
sampling and processing of BM aspirate, PB and PBSC and the
standardised procedures for performing and reporting on IC and
QRT-PCR results.
Sampling for IC and RT–PCR and sample transport
Guidelines for sampling from BM, PB and PBSC were developed
and are detailed in Figure 1.
The volumes for IC and QRT-PCR are withdrawn from the same
collection tube containing anticoagulant to facilitate a comparison
of the sensitivity of IC and QRT-PCR for detection of MD within
the same clinical sample. Sampling of two sequential BM aspirates
for IC and QRT-PCR is not recommended because they are likely
to differ in cellularity, reflecting dilution of multiple sequential BM
Sampling for immunocytology and RT-PCR 
Bone marrow (BM):
1. Place the first BM aspirate (2-5 ml) from each iliac crest into 
    anticoagulant (EDTA or Heparin).   
2. Mix aspirate and anticoagulant gently by inverting the tube 3 to 5 times.   
3. Withdraw 0.5 ml of sample, place immediately into a PAXgene blood 
    RNA tube (Becton and Dickinson, cat. No. 762165), mix gently and send to  
    national reference centre within 48 hours at room temperature. 
4. Measure volume of remainder, dilute with equal amount of RPMI 1640 and  
    prepare for IC or send to national reference centre within 24 hours at room  
    temperature. 
Peripheral blood (PB):
1. Draw 5 ml PB and place into anticoagulant (Heparin or EDTA).  
2. Mix PB and anticoagulant gently by inverting the tube 3 to 5 times. 
3. Withdraw 2 ml and place immediately into a PAXgene blood RNA tube,  
    mix gently and send to national reference centre within 48 hours at room  
    temperature. 
4. Measure volume of remainder, dilute with equal amount of RPMI 1640 and  
    prepare for IC or send to national reference centre within 24 hours at room  
    temperature. 
Peripheral blood stem cell harvest:
1. Withdraw 0.5ml, place immediately into a PAXgene blood 
    RNA tube and send to national reference centre within 48 hours at room  
    temperature. 
2. Dilute remainder of the sample with equal amount of RPMI 1640 and  
    prepare for IC or send to national reference centre within 24 hours at room  
    temperature.
Figure 1 Consensus guidelines for sampling bone marrow (BM),
peripheral blood (PB) and peripheral blood stem cell (PBSC) harvest for
immunocytology (IC) and reverse transcriptase (RT)–PCR.
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stabilisation and extraction efficiency using the PAXgene blood
RNA tubes is unaffected by the anticoagulants EDTA or heparin.
Because processing of cells for IC includes counting of mono-
nuclear cells, the approximate number of mononuclear cells
analysed by QRT-PCR can be indirectly calculated if the sample
has been split in the way described and the volume analysed by
QRT-PCR has been accurately measured. A direct comparison of
the sensitivity of both methods, that is number of NB cells and
number of TH transcripts per number of cells analysed, is not
possible because the RNA for QRT-PCR is extracted from all BM
cells, whereas IC analyses only the mononuclear cell population.
However most importantly, the independent prognostic and
predictive power of the methods can be compared using multi-
variant analyses.
Some studies have shown that the number of circulating NB cells
detected by IC is approximately 2 logs higher in BM than in PB
(Faulkner et al, 1998), consistent with observations using QRT-PCR
where the level of TH mRNA transcripts may be up to 3 logs
greater in BM than the level observed in paired PB (Corrias et al,
2008). Neuroblastoma cells in PB are not currently used to assess
disease status in children with NB; however this may be relevant
for MD monitoring and could provide a less invasive test that is
better tolerated by most children (Cheung et al, 2004). Conse-
quently the INRG Metastatic Disease Monitoring Group recom-
mends that PB in addition to BM samples should be screened for
MD (Cheung et al, 2004).
If the BM sample size is 0.5ml or less this sample should be
taken for QRT-PCR, whereas the sample from the other iliac crest
should be analysed by IC. Peripheral blood samples of 2ml or less
should be analysed by QRT-PCR given the lower frequency of
circulating NB cells in blood.
Sample transport Dilution of the IC sample with RPMI 1640 helps
to maintain cell viability (K Beiske, unpublished observation).
Samples for IC should be maintained and transported to the
reference centre at room temperature. Processing samples for IC
should start within 24h of sample collection. If processing is
delayed until 48h, the sample can still be analysed, but a note
should be made and included into the final report. Samples
collected into PAXgene blood RNA tubes should be sent to the
reference centre within 48h at room temperature, or can be stored
locally at  801C for up to 12 months before analysis. Frozen
samples can be transported to reference centres on dry ice. RNA is
stable in PAXgene blood RNA tubes stored at  801C for more than
12 months.
IC analysis
Of the single-cell-based methods reviewed IC was chosen because
it reaches a higher sensitivity than FC. Immunocytochemistry was
preferred to fluorescence-based IC because screening in a light
microscope facilitates the recording of cytomorphological details
requisite for final evaluation. Moreover and in contrast to
fluorescence-based methods, immunocytochemical staining
products are permanent and can be reviewed in a multi-headed
light microscope, which facilitates quality control, consensus
diagnoses in difficult cases, definition of standard criteria for
evaluation and training of newcomers in the field.
The recommendations summarised in Figures 2 and 3 represent
slight modifications of the previously published European IC
consensus method (Swerts et al, 2005). Figure 2 describes the
procedures for cell preparation and immunocytochemical staining.
Step 1 of the cell preparation is skipped when handling PBSC
products. If the cell number in any type of sample exceeds 3 10
6,
extra slides should be made and frozen without prior fixation at
 801C for back up, for example additional investigation with other
markers. If frozen slides are unwrapped before thawing, the
Immunocytological analysis (1)
Cell preparation
1. Isolate mononuclear cells by density gradient centrifugation using Lymphoprep  
    (Nycomed, Oslo, Norway) and count cells. 
2. Spin about 5x10
5 cells on large diameter (17mm) pre-coated cytospins using a 
    Hettich centrifuge (Hettich Zentrifugen, Tuttlingen, Germany) (speed: 1000 and  
    3000 RPM, respectively). 
3. Prepare at least 3x10
6 cells (6 slides) from each sample. 
4. Air-dry cells overnight, wrap up to 5 slides in aluminium foil and keep at -80°C  
    until use. 
5. When >3x10
6 cells are available, prepare 6 extra slides for back up and  
    additional investigations, air-dry and freeze unfixed at -80°C.    
Immunocytochemical staining
1.  Thaw slides while still wrapped and remove aluminium foil first when slides   
     have reached room temperature. 
2.  Fix slides in 4% buffered, methanol-free paraformaldehyde for 10 min. 
3.  Wash three times in PBS. 
4.  Incubate slides for 30 min with monoclonal mouse anti-GD2 disialoganglioside  
     antibody (clone 14.G2a; Pharmingen, San Diego, CA, USA) diluted 1/100 in 
     1% PBS/BSA. 
5.  Wash twice in PBS for 5 min. 
6.  Incubate slides for 30 min with rabbit anti-mouse antibody (Dako, Glostrup, 
     Denmark) diluted 1/20 in 1% PBS/BSA. 
7.  Wash twice in PBS for 5 min. 
8.  Incubate with APAAP complex (Dako) diluted 1/20 in 1% PBS/BSA. 
9.  Incubate with Dako Fuchsin+ Substrate-Chromogene System (Dako) for up to     
     10 min. 
10. Wash in running tape water for at least 5 min. 
11. Counterstain with hematoxylin (Sigma Aldrich, St Louis, MO, USA).  
12. Mount with cover slip in aqueous mounting medium (e.g. Glycergel, Dako). 
Figure 2 Immunocytological analysis. Consensus guidelines for cell
preparation and immunocytochemical staining. Abbreviations: r.p.m.,
rounds per min; PBS, phosphate-buffered saline; BSA, bovine serum
albumin; APAAP, alkaline phosphatase anti-alkaline phosphatase.
Immunocytological analysis (2) 
Light microscopic evaluation 
1. Apply evaluation criteria: 
    a. Cytomorphological inclusion criteria:
        - Round nucleus, often (but not always) larger than small lymphocytes 
        - Cytoplasmic rim not broader than half of the largest diameter of the     
          nucleus 
        - Granular chromatin structure (not always present, therefore not obligate) 
    b. Immunological inclusion criteria:
        - Strong, deeply red and complete membrane (and may be additional     
          cytoplasmic) staining 
    c. Immunological exclusion criteria:
        - Moderate/weak cytoplasmic and negative membrane staining 
        - Staining restricted to cytoplasmic compartments (vacuoles) 
        - Staining covering the nucleus and thereby hindering assessment of  
          nuclear/cytoplasmic ratio 
        - Staining due to shedding of antigen from other cells 
        - Staining of amorphous, anuclear material (e.g. fragments of neuropile) 
2. Categorize cells into 
    - Criteria-positive cells (CPC): immunostained cells completely fulfilling all     
      morphological and immunological inclusion criteria 
    - Not convincingly interpretable cells (NCIC): immunostained cells not   
      completely fulfilling all morphological and immunological inclusion criteria   
    - Haematopoietic cells (HC): immunostained cells which by cytomorphology   
      can be identified as macrophages, myeloid/histiocytic cells or erythroblasts  
Cell counting and reporting
1. Count CPCs on all slides and report total number. If CPC number on one  
    slide exceeds 100, the percentage of CPC may be reported. 
2. Count NCICs on all slides and report total number. If NCIC number on one  
    slide exceeds 100, the percentage of NCIC may be reported. 
3. If overlaying cells in cell clumps cannot be counted, report number of clumps  
    and estimated cell number per clump. 
4. Do not count cells only displaying exclusion criteria and haematopoietic cells. 
5. Number of investigated cells: 
    - Count 3-5 representative optic fields on each slide using x40 objective. 
    - Calculate average number of cells per optic field. 
    - Multiply number of cells per optic field with number of optic fields per total  
      cytospin area. 
    - Sum up and report investigated cells on all slides.  
Figure 3 Immunocytological analysis. Consensus guidelines for light
microscopic evaluation, cell counting and reporting of results.
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sformation of condensation will make the slides stick together and
possibly destroy cell morphology. Thawed slides detach without
problems. For freezing, wrapping in aluminium foil is preferred to
plastic boxes because boxes consume too much space and do not
prevent condensation. Locally prepared cytospins can be kept
frozen at  801C, batched and sent on dry ice to the reference
centre for immunostaining.
Paraformaldehyde fixation should be performed by incubating
single slides on a staining bridge and not in a jar to avoid crossover
contamination of single cells between individual slides. Parafor-
maldehyde is crucial to provide reproducible maintenance of
cytomorphological details required for final evaluation (Figure 3).
Acetone is an inappropriate fixative in this context because it
permits swelling of cells with subsequent changes in nuclear/
cytoplasmic ratio and even loss of nuclear material.
The INRG Committee for Detection of MD recommends
monoclonal anti-GD2 antibody 14.G2a (Mujoo et al, 1987; BD
Biosciences, Pharmingen, San Diego, CA, USA). GD2 was chosen as
the target for IC because it is known to be strongly expressed by
most neuroblastic tumours, but not by normal haematopoietic
cells (Cheung et al, 1986) as detailed in the beginning. Presently,
no other neuroblastic antigen with similar qualities is known.
Schumacher-Kuckelkorn et al (2005) reported a heterogeneous
weak or negative GD2 staining of infiltrating NB cells in the BM in 1
of 191 patients (0.5%) before treatment. The INRG Committee for
Detection of MD recommends investigation of BM and PB already
at diagnosis (see below) to identify these very rare primarily
negative cases. In the same report, two other patients with
originally strongly GD2-positive BM infiltration were found
negative after anti-GD2 treatment, which might be explained by
antigen modulation or selection of GD2-negative clones through
therapy. Loss of GD2 after antibody treatment is considered to be
very infrequent by others (Kramer et al, 1998). If anti-GD2 staining
is found to be negative in cytomorphologically positive cases, other
antibodies, for example anti-CD56, should be applied that show
high sensitivity for NB cells but lower specificity than GD2.
For positive control of anti-GD2 immunostaining, cytospins from
NB cell lines (eg IMR-32) should be included. Unspecific staining
can be ruled out by evaluating normal BM cells in the sample, which
are supposed to be completely negative for GD2 staining. Titrating
new batches of antibodies and alkaline phosphatase anti-alkaline
phosphatase (APAAP) complexes should also be performed on NB
cell lines and normal BM until strong staining of NB cells but
absence of staining in normal BM cells is reached.
Figure 3 summarises the criteria for light microscopic evalua-
tion, cell counting and reporting of results. Not convincingly
interpretable cells (NCICs) are cells that by morphology are typical
neuroblasts, but show either only weak or incomplete membrane
staining, or vice versa, that is cells smaller than typical neuroblasts
but displaying complete or incomplete membrane staining. Not
convincingly interpretable cells are most frequently observed in
samples taken after treatment and often colocalised with typically
stained neuroblasts. They might represent tumour cells which are
degenerated after chemotherapy and should be registered and
reported separately to establish if they have the same prognostic
impact as those cells fulfilling all inclusion criteria. Examples of
convincingly interpretable cells (CPCs), false positivity of normal
cells due to antigen shedding, a well-known phenomenon in NB
(Ladisch et al, 1987), NCICs and normal macrophages having
ingested GD2 are presented in Figure 4.
QRT-PCR analysis
Quantitative reverse transcriptase-polymerase chain reaction for
tissue-specific mRNAs provides an objective assay for the
detection of MD and MRD with a numeric readout across a wide
linear dynamic range. However the clinical benefit of QRT-PCR for
detection of disease will most likely come from the sensitivity and
specificity with which low-level disease (o10%) is detected. To
minimise intra- and inter-assay variability across different
laboratories, SOPs for the optimal analysis and reporting of MD
detected by QRT-PCR for TH mRNA in haemopoietic compart-
ments have been established (Viprey et al, 2007). These SOPs have
been adopted by the INRG Metastatic Disease Committee and are
summarised below.
As with all PCR-based assays cautions are taken to avoid
contamination of samples; RNA is extracted from clinical samples
in a designated RNA room, RT–PCR is set-up and performed in a
second room, and PCR is performed using the TaqMan assay
(PerkinElmer, Applied Biosystems, Foster City, CA, USA), in a
third room. Single-use aliquots of dNTPs, primers, probes and
buffers are prepared to avoid freeze–thaw artefacts. All consum-
ables are RNAse free, and gloves are worn to prevent the transfer
of RNases onto the tubes from the hands. All clinical samples are
clearly labelled with a unique identifier, catalogued and stored in a
designated  801C freezer.
RNA is extracted from PB (2ml), BM (0.5ml) or PBSC (0.5ml)
stabilised in PAXgene blood RNA tubes using the PAXgene
blood RNA kit according to the manufacturer’s instructions, with a
DNAse digestion step before elution of RNA from the column. In
brief, after digestion with proteinase K the stabilised haemopoietic
sample is added to the RNA extraction column, the flow-through is
discarded, DNAse (1350U; 10ml) is added to the column and
incubated for 15min at room temperature. This step is to remove
any contaminating DNA; we have found digestion of contaminat-
ing DNA while RNA is bound to the column removes any DNAse-
dependent non-specific digestion of RNA. The material bound to
the column is washed twice and eluted in buffer BR5 (company
proprietary); the 40ml elution volume is passed twice through the
column to maximise yield and concentration. The concentration
and purity of RNA are evaluated by measuring the optical density
of the RNA solution at 280 and 260nM; the Nanodrop ND-100
(www.labtech.co.uk) allows accurate analysis of 1ml volumes and
so is suitable for quantification of small precious clinical samples
without the need to dilute them. RNA samples (o1mgml
 1) are
stored in 10ml aliquots at  801C.
cDNA is synthesised from 10ml of RNA (400ng) for 1h at 371C,
reverse transcriptase enzyme is inactivated by heating at 951C for
5min and amplified using the TaqMan assay as previously
described (Viprey et al, 2007). Each sample is amplified in
triplicate (3  cDNA from 100ng RNA) for TH mRNA and once
(1 80ng) for the housekeeping gene b2M. Negative controls of
RNA with no reverse transcriptase enzyme are included to confirm
the specificity of amplification from cDNA and not contaminating
DNA. A positive control of cDNA generated from IMR-32 RNA
(800pg) in RNA isolated from PB from healthy volunteers (400ng)
is included to monitor any inter-assay variability. This control is
also important to standardise reporting of data from clinical
sample analyses that are made according to the comparative
Ct method (Livak and Schmittgen, 2001) to provide an objective
read-out of TH mRNA. Using this method the level of TH mRNA
is normalised to expression of the housekeeping gene b2M
and reported relative (fold difference) to the positive
control sample according to the formula: 2
 DDCt, where
DDCt¼((CtTH Ctb2M)Sample (CtTH Ctb2M)Positive control). Ideally
the positive control should be provided by a central reference
laboratory to avoid any variation attributed to differences in cell line
expression of TH mRNA and sample preparation. To maintain
integrity of the data, analysis and reporting from studies on clinical
samples should be made independent of knowledge of other
prognostic or predictive factors and patient disease status (Figure 5).
Time points
It is recommended that analysis of BM and PB for MD should be
performed at diagnosis, at the end of induction treatment (before
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stransplantation), before treatment for MRD and at the end of
therapy. Peripheral blood stem cell preparations should be
analysed at the time of harvest. The demonstration of tumour
cells in BM during initial staging currently remains dependant on
morphology alone as detailed in the INRGSS (Monclair et al, 2009).
It is, nevertheless, strongly recommended that BM and PB sampled
at the time of diagnosis are analysed by IC and QRT-PCR to obtain
baseline information on specific antigen or mRNA expression, and
to investigate the potential clinical significance of MD in those
children who appear not to have metastatic disease using
conventional methods at diagnosis.
DISCUSSION
Key features of IC and QRT-PCR for detecting NB cells in BM, PB
and PBSC are high specificity, sensitivity and precise quantifica-
tion of cell or transcript number. For initial INRG staging,
AB C
DE F
GH I
JK L
Figure 4 (A–L) Immunostaining of cytospins containing mononuclear cells from BM aspirates pulled from children with NB stage M. The red label shows
binding of monoclonal anti-GD2 antibody 14.G2a visualised by a commercial alkaline phosphatase anti-alkaline phosphatase kit and Fuchsinþ substrate
(Swerts et al, 2005). All images are taken with a  60 dry lens and reproduced with identical magnification to enable comparison of different cell types by
size. A and B show the mandatory cytomorphological and immunological criteria of neuroblasts, that is high nuclear/cytoplasmic ratio and strong GD2
membrane expression. A granular appearance of the chromatin is frequently, but not always recognised. Neuroblasts are usually larger than small
lymphocytes (arrows). If all criteria are fulfilled, even single neuroblasts can be identified (B). Reliable recognition of cytomorphological and immunological
criteria depends on paraformaldehyde fixation. (C) Typical clump formation of neuroblasts with moulding nuclei. Some tumour cells may show increased
amount of cytoplasm (arrow), but the nuclear/cytoplasmic ratio should not decline below 2. Note adjacent GD2-negative lymphocytes. Cells that fulfil the
criteria as detailed in A–C are classified as criteria-positive cells (CPC). (D–F) Shedding of GD2 from a clump (D) or a single neuroblast (arrow in E)o n
adjacent haematopoietic cells creates the impression of an almost complete (arrow in D) or partial membrane staining. GD2 may even shed from fibrillary
acellular material, for example fragment of neuropile (arrow in F) on to normal cells. Note: no neuroblasts are identified in F.( G–I) Not convincingly
interpretable cells (NCICs). Two of the cells in G (arrows) do not display a complete membrane staining. However, their nuclear size, morphology and
clump formation strongly favour a neuroblastic origin. In H, form and size of the nucleus suggest a neuroblast, but the cell membrane is widely avoided of
GD2. Also the cell in I is incompletely stained and in addition somewhat smaller than typical neuroblasts. The true nature of these cells can only be revealed
by means of ancillary methods (eg FISH, single-cell PCR). Their potential clinical significance remains to be established. (J–L) Macrophages with ingested
GD2 are often found after chemotherapy and must not be interpreted as tumour cells. Hallmarks of macrophages are a very low nuclear/cytoplasmic ratio
(usually o1), a granular compartmentalisation of the antigenic material in vesicles and a negative membrane stain (arrows in J–L), although the label may
even occupy the whole cytoplasm (L). The colour quality of ingested GD2 is usually not purple red as in neuroblasts (see A–E), but rather brownish due to
increased iron storage after blood transfusions.
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smorphological assessment will be performed to identify patients
with metastatic disease (INRGSS M and MS). However, to collect
baseline information on the presence of specific targets in the
tumour cells, IC and RT–PCR should also be performed at
diagnosis. Moreover, tumour cell infiltration identified by IC or
RT–PCR in the BM of INSS stage 1–3 patients (Moss et al, 1991)
suggests that these children may benefit from upstaging and more
aggressive therapeutic strategies, and could result in a re-definition
of what constitutes disease free. It is crucial that further studies are
performed using standardised methods for the detection of MD in
a larger patient cohort. The increased sensitivity of NB detection at
diagnosis might improve identification of some children for
treatment with improved outcome. Furthermore, the unequivocal
demonstration of MRD after chemotherapy may have important
consequences for the clinical management of these children. It is
conceivable that children in remission with no evidence of MRD
may be spared further cytotoxic therapy, thereby reducing
treatment-related complications. In children with proven meta-
static disease, detection of MRD may better define response in BM
and PB during successive cycles of chemotherapy. Minimal
residual disease may also be used to evaluate objectively the
efficacy of distinct strategies of adjuvant therapy, that is
myeloablative therapy with autologous BM/PBSC rescue, or
biological approaches like immunotherapy/differentiation therapy
(Cheung et al, 2003). Finally, detection of MRD in PBSC may also
be important if the re-infusion of NB cells leads to relapse (Brenner
et al, 1994; Brenner, 1995), providing an objective method to
identify harvests free of tumour cells for optimal use in
transplantation and to evaluate the efficacy of purging techniques.
Both IC and QRT-PCR detect NB cells with increased sensitivity
than more conventional cytology. However it is important to
remember that although tumour cells in BM, PB or PBSC have the
capacity to metastasise they will not necessarily go on to form
secondary disease, as this is dependant on other biological
processes (Eccles and Welch, 2007). It is therefore critical to
evaluate the clinical significance of detecting MD or MRD in
quality-controlled prospective clinical trials facilitating the inter-
pretation of MD data in relation to patient age, stage, genetic
markers and treatment modalities. The introduction of the above
SOPs will allow a comparison of data between participating centres
and across different studies to more efficiently evaluate the clinical
significance of MD and MRD detected by IC and QRT-PCR, while
also allowing a direct comparison of efficiency of treatments for
MD. In such studies the limitations and advantages of IC and QRT-
PCR must be considered.
Immunocytology sample preparation and immunostaining are
easily standardised and reproducibly performed in routine
cytological laboratories, especially if an automatic staining device
is available that in addition facilitates high sample throughput. The
correct application of cytomorphological and immunological
evaluation criteria necessitates careful cytological examination by
a trained investigator to ensure reproducible and comparable
results. Immunocytochemically stained slides are well suited to
create training sets. They may be batched after production in local
laboratories and collected for central review by expert panels. The
application of consensus criteria for immunological and morpho-
logical evaluation of anti-GD2-stained BM samples and the
establishment of criteria for selecting critical samples for central
review have led to a significant improvement of inter-observer
concordance among the participants of a European multi-centre
study (Swerts et al, 2005).
An important advantage of IC is the ability to quantify the
number of tumour cells and normal cells in each specimen,
because the total number of analysed cells defines the sensitivity of
each individual investigation. To obtain a sensitivity of one
tumour cell detected in 1 10
6 normal cells, the analysis of 3 10
6
PB and BM cells is required (Cheung et al, 1986). If the absolute
number of tumour cells is critically important for the clinical
development of metastases, it is anticipated that IC may lead to an
objectively defined cell number that predicts outcome for future
risk grouping and stratification for therapy.
In contrast QRT-PCR does not measure absolute tumour cell
number, although the quantitative standardised detection of target
mRNAs permits an accurate assessment of tumour load across
samples and patients. The main advantages of QRT-PCR for the
detection of MD are the simplicity with which samples are
optimally collected and processed, the transferability of the assays
and the objective numeric end point.
For both assays the evaluation of samples with several
antibodies or for multiple mRNA species may increase the
specificity of MD and MRD detection in heterogeneous samples.
Marker discovery based on differential gene expression profiling,
stringent sensitivity and specificity assays, and well-annotated
patient samples can rapidly prioritise and identify novel MRD
markers of NB (Cheung et al, 2008). Interestingly a combination of
techniques or targets might provide not only prognostication
about the clinical significance of MD but could also provide
additional biologically relevant information. For example the
National / international
reporting database
cDNAsynthesis: RNA (400 ng in 10 l)+ 10 l RT mix
Real-time PCR: Sample (S) and positive control (PC)
(S). cDNA (16 l) + TH mix (64 l) = 3 × 25 l
(PC). cDNA(4 l) + H2O (1 l) + 2M mix (20 l) = 25 l
REPORTING 2–∆∆Ct
∆Ct=CtTH-Ct2M
∆∆Ct=∆CtSample-∆CtPositive control
Storage–80°C for up to 12 months
PAXgeneTM blood RNA tubes
RNA extraction: PAXgeneTM blood RNA kit
Quantity and quality of RNA determined; OD
RNA stored in aliquots; 1mg ml–1 at –80°C
Transport
in  PAXgeneTM blood RNA tubes
to reference centre within 48 h at room temperature 
Figure 5 RNA is extracted and processed for detection of mRNA by
QRT-PCR according to standard operating procedures.
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sexpression of specific target mRNAs may identify profiles that are
prognostic or predictive of the behaviour of the metastatic tumour
cell (Wagner et al, 2006; Grau et al, 2009). Alternatively analysis
using multiple complementary methods may be valuable to define
prognostic/predictive groups, for example the coupling of anti-GD2
antibodies with antibodies against proliferation markers or with
DNA probes capable of detecting genetic alterations of prognostic
significance (Me ´hes et al, 2001). In contrast to methods based on
extracting DNA, RNA or proteins from clinical samples, the cell-
based nature of IC or of cytogenetic analyses permits monitoring
possible heterogeneous expression patterns of biologically relevant
markers within a population of circulating tumour cells. In situ
hybridisation or single-cell PCR should at least be considered for
samples only presenting NCICs as proposed by the SIOP European
Neuroblastoma group (Swerts et al, 2005). However, the INRG
Committee for Detection of MD regards these techniques too
expensive and specialised to be recommended as standard facili-
ties in all laboratories working on MD in NB. Nevertheless, saving
supplementary slides and RNA samples is strongly recommended
because new techniques and markers will emerge in the future. The
methods and targets for MD analysis proposed in this paper should
not be regarded as final, but will be revised when appropriate.
Despite the increased sensitivity of IC and QRT-PCR to detect
NB cells, it is clear that cells are not detected in BM or PB of all
children with high-risk disease, reflecting the biological process of
metastases, the limitation of analysing a small sample volume and/
or possibly the heterogeneity of NB cells. To determine whether
tumour heterogeneity is significant in MRD surveillance, multiple
independent techniques, for example the inclusion of both IC and
QRT-PCR for the assessment of MRD in each clinical sample, or
the analysis of samples using multiple antibodies or amplifying for
several target mRNAs are desirable (Cheung et al, 1998). To
evaluate the impact of IC and QRT-PCR, alone and in combina-
tion, on the detection of clinically significant disease it was agreed
that BM, PB and PBSC samples will be divided using a standard
procedure after sampling. In the future, the utility of multiple
markers for IC and QRT-PCR will be evaluated and their utility
compared to the standards described in this paper. Before any
single or panel of markers can be introduced as a reliable
parameter for the evaluation of clinically relevant MD or MRD,
their clinical significance must be demonstrated in large prospec-
tive cooperative multi-centre studies, performed according to
SOPs. The methodological recommendations for the performance
of IC and QRT-PCR proposed by the INRG subcommittee in this
report may serve as a first step in an international effort that aims
to identify and validate MRD markers for clinical application.
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